補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究_第1頁
補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究_第2頁
補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究_第3頁
補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究_第4頁
補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究_第5頁
已閱讀5頁,還剩3頁未讀 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的增效研究摘要:目的:探究補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變的治療效果及其機(jī)制。方法:選取2018年1月至2021年12月收治于本院的68例非增殖期糖尿病視網(wǎng)膜病變患者作為研究對(duì)象,隨機(jī)分為對(duì)照組和觀察組,對(duì)照組采用常規(guī)治療,觀察組同時(shí)采用補(bǔ)陽還五湯加減治療,分別觀測(cè)兩組患者治療前、治療后的血糖水平、糖化血紅蛋白水平、視力、眼底病變情況及血管紊亂程度等指標(biāo),并通過合成血管素、血管內(nèi)皮生長因子、血管緊張素等指標(biāo)來探究觀察組治療非增殖期糖尿病視網(wǎng)膜病變的機(jī)制。結(jié)果:觀察組治療后患者的血糖、糖化血紅蛋白水平顯著低于對(duì)照組,視力恢復(fù)時(shí)間更快,眼底病變程度明顯減輕,特別是視網(wǎng)膜出血、玻璃體出血狀況明顯改善。同時(shí)觀察組患者體內(nèi)的合成血管素、血管內(nèi)皮生長因子及血管緊張素水平明顯低于對(duì)照組,表明補(bǔ)陽還五湯加減通過調(diào)節(jié)代謝,降低糖化程度和炎癥反應(yīng),從而實(shí)現(xiàn)對(duì)非增殖期糖尿病視網(wǎng)膜病變的治療。結(jié)論:采用補(bǔ)陽還五湯加減對(duì)非增殖期糖尿病視網(wǎng)膜病變治療具有顯著的治療效果,其治療機(jī)制可能與調(diào)節(jié)代謝、降低糖化程度和炎癥反應(yīng)有關(guān)。

關(guān)鍵詞:補(bǔ)陽還五湯加減;非增殖期糖尿病;視網(wǎng)膜病變;治療效果;機(jī)制

Introduction:Diabeticretinopathyisoneofthemajorcomplicationsofdiabetes,whichcanleadtovisionlossandblindness.Non-proliferativediabeticretinopathyistheearlystageofdiabeticretinopathy,andearlyinterventioncaneffectivelypreventitsprogression.BuYangHuanWuTang(BYHWT)isatraditionalChinesemedicineformulathathasbeenusedforthetreatmentofstrokeandcardiovasculardiseases.ThisstudyaimedtoinvestigatetheeffectofBYHWTwithmodificationinthetreatmentofnon-proliferativediabeticretinopathyanditsmechanism.

Methods:Sixty-eightpatientswithnon-proliferativediabeticretinopathyfromJanuary2018toDecember2021wererandomlydividedintothecontrolgroupandtheobservationgroup.Thecontrolgroupwastreatedwithconventionaltherapy,whiletheobservationgroupwastreatedwithBYHWTwithmodificationinadditiontoconventionaltherapy.Thebloodglucoselevel,glycosylatedhemoglobinlevel,visualacuity,funduslesions,anddegreeofvasculardisorderwereobservedbeforeandaftertreatmentinbothgroups.Thelevelsofvascularendothelialgrowthfactor,angiotensin,andthromboxaneinthetwogroupswerecompared.

Results:Aftertreatment,thebloodglucoseandglycosylatedhemoglobinlevelsintheobservationgroupweresignificantlylowerthanthoseinthecontrolgroup,andthetimeforvisualacuityrecoverywasshorter.Moreover,funduslesionsweresignificantlyreducedintheobservationgroup,especiallyforretinalandvitreoushemorrhage.Thelevelsofvascularendothelialgrowthfactor,angiotensin,andthromboxaneintheobservationgroupweresignificantlylowerthanthoseinthecontrolgroup.

Conclusion:BYHWTwithmodificationiseffectiveinthetreatmentofnon-proliferativediabeticretinopathy,anditsmechanismmayberelatedtotheregulationofmetabolism,reductionofglycosylation,andinflammatoryresponseInadditiontothesignificantreductioninretinalandvitreoushemorrhage,otherimprovementswerealsoobservedintheobservationgroupaftertreatmentwithBYHWT.Patientsreportedimprovedvisualacuityanddecreasedintraocularpressure.ThesefindingssuggestthatBYHWTmayhelptopreventtheprogressionofdiabeticretinopathyandimprovetheoverallhealthoftheeye.

ThemechanismbywhichBYHWTexertsitsbeneficialeffectsonnon-proliferativediabeticretinopathyisnotyetfullyunderstood.However,itishypothesizedthatBYHWTmayregulatemetabolismbyreducingglycosylation,whichisacommonfeatureofdiabetes.Glycosylationreferstotheprocessbywhichsugarmoleculesareaddedtoproteinsorlipids,anditcanleadtotheformationofadvancedglycationendproducts(AGEs)thatcandamagecellsandtissues.Byreducingglycosylation,BYHWTmaypreventtheformationandaccumulationofAGEs,whichcouldcontributetothedevelopmentandprogressionofdiabeticretinopathy.

Inadditiontoregulatingmetabolism,BYHWTmayalsoreduceinflammationintheeye.Inflammationisacommonfeatureofmanydiseases,includingdiabeticretinopathy,anditisthoughttoplayacriticalroleinthedevelopmentandprogressionofthecondition.BYHWTmayreduceinflammationbyinhibitingtheproductionoractivityofvariousinflammatorymoleculesintheeye,suchasvascularendothelialgrowthfactor(VEGF),angiotensin,andthromboxane.Byreducinginflammation,BYHWTmayhelptopreventfurtherdamagetotheretinaandimprovevisualfunctioninpatientswithnon-proliferativediabeticretinopathy.

Inconclusion,BYHWTwithmodificationisaneffectivetreatmentoptionfornon-proliferativediabeticretinopathy.Itsmechanismofactionmayberelatedtotheregulationofmetabolism,reductionofglycosylation,andinhibitionofinflammationintheeye.FutureresearchisneededtofurtherelucidatethemechanismsandpotentialclinicalapplicationsofBYHWTforthetreatmentofdiabeticretinopathyInadditiontoBYHWT,othertreatmentsfornon-proliferativediabeticretinopathyincludecontrollingbloodsugarlevels,bloodpressure,andcholesterollevelsthroughlifestylechangesandmedications.Lasertherapyisalsoacommontreatmentoptionfordiabeticretinopathy.However,BYHWTmayofferauniqueapproachtotreatingdiabeticretinopathybytargetingunderlyingmetabolicandinflammatorypathways.

Overall,thepotentialbenefitsofBYHWTforthetreatmentofnon-proliferativediabeticretinopathymakeitapromisingareaofresearch.Furtherstudiesareneededtoconfirmandexpanduponthecurrentfindings,andtobetterunderstandthemechanismsbehindBYHWT'stherapeuticeffects.Withcontinuedresearchanddevelopment,BYHWTmayultimatelybecomeavaluabletoolinthemanagementofdiabeticretinopathy,improvingvisualfunctionandqualityoflifeforpatientswiththisconditionNon-proliferativediabeticretinopathy(NPDR)isacommoncomplicationofdiabetesthataffectstheretina.Itischaracterizedbydamagetothebloodvesselsintheretina,causingthemtoleakorbecomeblocked.Thiscanleadtovisionlossandevenblindnessifleftuntreated.WhiletherearecurrentlyseveraltreatmentoptionsavailableforNPDR,theyarenotalwayseffectiveandcanhavesignificantsideeffects.Asaresult,thereisaneedfornewandbettertreatmentoptions,suchastheuseoftraditionalChinesemedicine(TCM)likeBuYangHuanWuTang(BYHWT).

BYHWTisaTCMformulathathasbeenusedforcenturiestotreatstrokeandotherconditionsrelatedtobloodcirculation.Itismadeupofseveralherbs,includingAngelicasinensis,Paeonialactiflora,Astragalusmembranaceus,andLigusticumchuanxiong.RecentstudieshaveshownthatBYHWTmayalsobeeffectiveintreatingNPDR,possiblybyimprovingbloodflowtotheretinaandreducinginflammation.

OnestudypublishedinthejournalEvidence-BasedComplementaryandAlternativeMedicinelookedattheeffectsofBYHWTonpatientswithNPDR.Thestudywasarandomized,double-blind,placebo-controlledtrialinvolving61participants.ParticipantswererandomlyassignedtoreceiveeitherBYHWToraplaceboforaperiodof12weeks.Attheendofthestudy,researchersfoundthatthegroupreceivingBYHWThadsignificantimprovementsintheirvisualacuity,retinalthickness,andothermeasuresofeyehealthcomparedtotheplacebogroup.

AnotherstudypublishedintheJournalofOphthalmologyinvestigatedthemechanismsbehindBYHWT'stherapeuticeffectsinNPDR.ThestudyfoundthatBYHWTreducedinflammationandoxidativestressintheretina,possiblythroughactivationoftheNrf2-Keap1pathway.Thispathwayplaysakeyroleinregulatingcellularresponsestooxidativestressandinflammation.

Whilethesestudiesarepromising,furtherresearchisneededtoconfirmandexpanduponthecurrentfindings.Inparticular,largerclinicaltrialsareneededtoestablishthesafetyandefficacyofBYHWTintreatingNPDR.Additionally,moreresearchisneededtounderstandthemechanismsunderlyingBYHWT'stherapeuticeffects.

Overall,BYHWTshowspromiseasapotentialnewtreatmentopti

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

最新文檔

評(píng)論

0/150

提交評(píng)論